CDMO Quality Management System

Shanghai OPM Biosciences Co., Ltd. has established a quality management system covering the entire life cycle of drugs covering production systems, plant facilities and equipment systems, laboratory control systems, material systems, packaging and labeling systems in accordance with the Good Manufacturing Practices for Drugs (2010 Edition), the Quality Management Practice for Non-Clinical Research of Drugs (Order [No. 34] of the State Food and Drug Administration (now National Medical Products Administration, NMPA)), and the ICHQ10 Pharmaceutical Quality System, including the management responsibilities to meet customer needs, process operation and continuous improvement of product quality.

The continuous improvement system of the quality management system, combined with quality risk management, data reliability management, technology transfer management and verification management, ensures the continuous and stable production of drugs that meet the intended use and registration requirements.


The OPM quality management system, covering the whole life cycle of drugs, is compliant with China/EU/US GMP requirements

  • Good Laboratory Practice (GLP)for Non-Clinical Research of Drugs (2017)
  • Good Clinical Practice (GCP) for Clinical Trials of Drugs (2020)
  • Good Manufacturing Practice (GMP)(2010)


Principles of End-to-End Biologics CDMO's quality management system

The Quality System of End-to-End Biologics CDMO

End-to-End Biologics CDMO's quality management system is based on FDA´s six quality systems

End-to-End Biologics CDMO's Quality Management System meets the requirements of modern drug development processes

Contact Us

Building #28, 908 Ziping Road, Pudong, Shanghai, China

+86 021-2078 0255 (General)

+86 021-6818 2622 (Salesline)

+86 021-6810 1106 (CDMO BD) (Customer Service Email) (Sales Email) (CDMO BD Email)

Scan the QR code and follow our official WeChat account

Copyright © 2015-2022 Shanghai OPM Biosciences Co., Ltd. All Rights Reserved.

Order Products